Goudot C, Coillard A, Villani A-C, et al. Aryl Hydrocarbon Receptor Controls Monocyte Differentiation into Dendritic Cells versus Macrophages. Immunity. 2017;47(3):582-596.e6. doi:10.1016/j.immuni.2017.08.016.

Wheeler MA, Rothhammer V, Quintana FJ. Control of immune-mediated pathology via the aryl hydrocarbon receptor. J Biol Chem. 2017;292(30):12383-12389. doi:10.1074/jbc.R116.767723.

Natividad JM, Agus A, Planchais J, et al. Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. Cell Metab. 2018;28(5):737-749.e4. doi:10.1016/j.cmet.2018.07.001.

Gutiérrez-Vázquez C, Quintana FJ. Regulation of the Immune Response by the Aryl Hydrocarbon Receptor. Immunity. 2018;48(1):19-33. doi:10.1016/j.immuni.2017.12.012.

Dolciami D, Gargaro M, Cerra B, et al. Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist. ChemMedChem. 2018;13(3):270-279. doi:10.1002/cmdc.201700669.

Rothhammer V, Borucki DM, Kenison JE, et al. Detection of aryl hydrocarbon receptor agonists in human samples. Sci Rep. 2018;8(1):4970. doi:10.1038/s41598-018-23323-4.

Rothhammer V, Borucki DM, Tjon EC, et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557(7707):724-728. doi:10.1038/s41586-018-0119-x.

Weinert BT, Narita T, Satpathy S, et al. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome. Cell. 2018;174(1):231-244.e12. doi:10.1016/j.cell.2018.04.033.

Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-7. doi:10.1038/nature11003.

Mascanfroni ID, Takenaka MC, Yeste A, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med. 2015;21(6):638-46. doi:10.1038/nm.3868.